8-K filed May 15, 2024, 7:59 PM ET ticker SNDX CIK 0001395937

leadership confidence high sentiment positive materiality 0.55

Syndax appoints Aleksandra Rizo to Board; Morrison resigns; annual meeting votes passed

Syndax Pharmaceuticals Inc

Aleksandra Rizo, M.D., Ph.D., elected to Board effective May 15, replacing Briggs Morrison who resigned.
Dr. Rizo receives $45,644 annual cash for Board service, $8,558 for Science & Technology Committee, plus initial option for 35,000 shares vesting monthly over three years.
Annual meeting results: all director nominees elected (Huber 61.9M for, Jarrett 39.5M for), executive compensation advisory vote passed (46.2M for, 16.3M against), auditor ratified (65.4M for).
Dr. Rizo is President/CEO of Vividion, brings hematology clinical development and regulatory experience.

item 5.02 item 5.07 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Aleksandra Rizo

Director

SNDX · Syndax Pharmaceuticals Inc

Effective: 2024-05-15
Filed: May 15, 2024, 7:59 PM ET

On May 15, 2024, the Board of Directors (the “ Board ”) of Syndax Pharmaceuticals, Inc. (the “ Company ”), unanimously voted to elect Aleksandra Rizo, M.D., Ph.D. to the Board, effectively immediately

Departed

Briggs W. Morrison

Director

SNDX · Syndax Pharmaceuticals Inc

Effective: 2024-05-14
Successor: Aleksandra Rizo
Filed: May 15, 2024, 7:59 PM ET

On May 14, 2024, Briggs W. Morrison, M.D. advised the Board that he will resign from his position as a Class III member of our Board effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Aleksandra Rizo was elected as Director at Syndax Pharmaceuticals Inc.

Action: elected
Role: Director

Exact text from the filing

On May 15, 2024, the Board of Directors (the “ Board ”) of Syndax Pharmaceuticals, Inc. (the “ Company ”), unanimously voted to elect Aleksandra Rizo, M.D., Ph.D. to the Board, effectively immediately

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Briggs W. Morrison resigned as Director at Syndax Pharmaceuticals Inc.

Action: resigned
Role: Director

Exact text from the filing

On May 14, 2024, Briggs W. Morrison, M.D. advised the Board that he will resign from his position as a Class III member of our Board effective immediately.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Syndax Pharmaceuticals Inc shareholders approved Election of directors at the 2024-05-15 meeting.

Proposal: director election
Outcome: passed
Meeting: 2024-05-15

Exact text from the filing

Proposal 1 : Election of directors: Nominee For Withheld Broker Non-Votes Martin H. Huber, M.D. 61,876,711 736,625 3,032,770

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Syndax Pharmaceuticals Inc shareholders approved Advisory vote on executive compensation at the 2024-05-15 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2024-05-15

Exact text from the filing

Proposal 2 : Advisory vote on executive compensation: For Against Abstain Broker Non-Votes 46,228,421 16,304,796 80,119 3,032,770

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Syndax Pharmaceuticals Inc shareholders approved Ratification of selection of independent registered public accounting firm at the 2024-05-15 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2024-05-15

Exact text from the filing

Proposal 3 : Ratification of selection of independent registered public accounting firm: For Against Abstain Broker Non-Votes 65,371,337 253,270 21,499 —

View on SEC.gov

146 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0000950170-24-060462

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.